Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Msln (Mesothelin), Antxr1 (Tem8), and Muc3a Are the Potent Antigenic Targets for Car T Cell Therapy of Gastric Adenocarcinoma Publisher Pubmed



Sotoudeh M1, 2 ; Shirvani SI3 ; Merat S1, 4 ; Ahmadbeigi N3 ; Naderi M3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Liver and Pancreatobiliary Diseases Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Digestive Diseases Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Cell-Based Therapies Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Digestive Oncology Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran

Source: Journal of Cellular Biochemistry Published:2019


Abstract

Gastric adenocarcinoma is usually diagnosed in late stages, necessitating the use of different therapeutic modalities. Currently, antibody-based therapies have also been approved through with limited clinical efficacy. Reinforcing antibody-based immunotherapy by using chimeric antigen receptor (CAR) T cells may enhance the approach. However, the cells can cause severe on-target and off-tumor toxicities owing to their higher sensitivity to low-level antigen expressions. To address the need for safe and reliable targets, we made a bioinformatics pipeline by which we screened overexpressed genes in the disease for off-tumor sites in many normal tissues. Our inspection showed that MSLN (Mesothelin), ANTXR1 (TEM8), and MUC3A are the probable targets of CAR T cell therapy in gastric adenocarcinoma. The proposed antigenic targets might respond to the need to simultaneously target multiple antigens in a tumor matrix to prevent resistance. © 2018 Wiley Periodicals, Inc.
Related Docs
View other Related Docs
1. Antigenic Targets of Car T Cell Therapy. a Retrospective View on Clinical Trials, Experimental Cell Research (2018)
2. Antxr1 (Tem8) Overexpression in Gastric Adenocarcinoma Makes the Protein a Potential Target of Immunotherapy, Cancer Immunology# Immunotherapy (2019)
3. The Promising Role of Monoclonal Antibodies for Gastric Cancer Treatment, Immunotherapy (2019)
4. Decoding the Expression Pattern of Muc3a in Gastric Adenocarcinoma: Unveiling the Key to Successful Immunotherapy, Expert Opinion on Therapeutic Targets (2023)
5. Novel Car T Therapy Is a Ray of Hope in the Treatment of Seriously Ill Aml Patients, Stem Cell Research and Therapy (2021)
6. Immunotherapy of Gastric and Esophageal Cancers, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
7. Chimeric Antigen Receptor -T Cell Therapy: Applications and Challenges in Treatment of Allergy and Asthma, Biomedicine and Pharmacotherapy (2020)
8. Crispr/Cas9-Mediated Tgfβrii Disruption Enhances Anti-Tumor Efficacy of Human Chimeric Antigen Receptor T Cells in Vitro, Journal of Translational Medicine (2021)
Experts (# of related papers)
View all Related Experts
Hamid Reza Mirzaei (6)
Nima Rezaei (6)
Other Related Docs
9. Immunotherapeutic Approaches in Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2018)
10. Cancer Immunotherapy Confers a Global Benefit, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
11. Car T Cell Therapy in Solid Tumors; With an Extensive Focus on Obstacles and Strategies to Overcome the Challenges, International Immunopharmacology (2021)
12. Immunopathology and Immunotherapy of Non-Hodgkin Lymphoma, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2015)
13. Prospects for Chimeric Antigen Receptor (Car) Γδ T Cells: A Potential Game Changer for Adoptive T Cell Cancer Immunotherapy, Cancer Letters (2016)
14. Production of Car T-Cells by Gmp-Grade Lentiviral Vectors: Latest Advances and Future Prospects, Critical Reviews in Clinical Laboratory Sciences (2019)
15. Car-Modified T-Cell Therapy for Cancer: An Updated Review, Artificial Cells# Nanomedicine and Biotechnology (2016)
16. Interpatient Variability in Mesothelin Expression Necessitates Its Evaluation Before Gastric Cancer Immunotherapy, Immunotherapy (2022)
17. Immunotherapeutic Approaches in Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2019)
18. Immunotherapy of Cancers Comes of Age, Expert Review of Clinical Immunology (2017)
19. Focusing on Exosomes to Overcome the Existing Bottlenecks of Car-T Cell Therapy, Inflammation and Regeneration (2024)
20. Efficacy and Safety of the Irinotecan, Capecitabine, and Oxaliplatin (Iox) Regimen in Metastatic Gastric Cancer: A Single Arm Phase Ii Trial, Middle East Journal of Cancer (2019)
21. Car-T Cells: Early Successes in Blood Cancer and Challenges in Solid Tumors, Acta Pharmaceutica Sinica B (2021)
22. A Vhh-Based Anti-Muc1 Chimeric Antigen Receptor for Specific Retargeting of Human Primary T Cells to Muc1-Positive Cancer Cells, Cell Journal (2021)
23. Programmable and Multi-Targeted Cars: A New Breakthrough in Cancer Car-T Cell Therapy, Clinical and Translational Oncology (2021)
24. Anti-Tumor Activity of Neratinib, a Pan-Her Inhibitor, in Gastric Adenocarcinoma Cells, European Journal of Pharmacology (2019)
25. Predictive and Therapeutic Biomarkers in Chimeric Antigen Receptor T-Cell Therapy: A Clinical Perspective, Journal of Cellular Physiology (2019)
26. Prolonged Persistence of Chimeric Antigen Receptor (Car) T Cell in Adoptive Cancer Immunotherapy: Challenges and Ways Forward, Frontiers in Immunology (2020)
27. Construction and Functional Characterization of a Fully Human Anti-Mesothelin Chimeric Antigen Receptor (Car) Expressing T Cell, Iranian Journal of Allergy# Asthma and Immunology (2020)
28. Cellular and Molecular Basis of Therapeutic Approaches to Breast Cancer, Cellular Signalling (2023)
29. The Current Landscape of Car T-Cell Therapy for Solid Tumors: Mechanisms, Research Progress, Challenges, and Counterstrategies, Frontiers in Immunology (2023)
30. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells, Frontiers in Immunology (2018)
31. Solid Tumors Challenges and New Insights of Car T Cell Engineering, Stem Cell Reviews and Reports (2019)
32. Chimeric Antigen Receptor T-Cell Therapy for Breast Cancer, Future Oncology (2021)